% | $
Quotes you view appear here for quick access.

PetMed Express, Inc. Message Board

snowflakeformationxy 62 posts  |  Last Activity: 36 minutes ago Member since: Dec 15, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by joeflow77 May 1, 2015 9:57 PM
    snowflakeformationxy snowflakeformationxy 36 minutes ago Flag

    Nice post Joe.
    Genome Analysis:
    Current Procedures and Applications / Book
    Chapter eight discusses hyper-methylation in cancer.
    With DNA methylation, cancer cells show genome-wide site-specific CpG islands in promoter regions as the most epigenetic medication in cancer. CpG islands is becoming known as most importance in silencing /regulation of tumor suppressor and cancer genes per molecular pathways, controlling cancer development and progression.

    Body fluids specimens - markers are now in use. My insurance sents (yearly test) kits for specimen collections to be returned to lab.

  • Reply to

    FDA approval will come within a month

    by danq_94118 May 1, 2015 6:25 PM
    snowflakeformationxy snowflakeformationxy May 2, 2015 12:03 AM Flag

    Joeflow: Yes. .
    FDA - "off-label" Investigational Use of Marketed Drugs. Information sheet - Guidance for Int Review Board and Investigators.
    Second paragraph explains it in full.

  • Reply to

    FDA approval will come within a month

    by danq_94118 May 1, 2015 6:25 PM
    snowflakeformationxy snowflakeformationxy May 1, 2015 9:17 PM Flag

    1993 federal legislation requires insurance to cover medically appropriate cancer therapies. This law includes off-label uses if the treatment has been tested in careful research studies and written up in well-respected drug reference books or medical journals. In 2008, Medicare rules were changed to cover more off-label uses of cancer treatment drugs.

    More than one in five prescriptions written in the U.S. are for off-label therapies. The FDA regulates drug approval, but not drug prescribing.

    According to G. Caleb Alexander, MD, MS, a medical ethics advisor at U. Chicago "off label use is common." "That virtually every drugs is used off-label..."

    Doctors are not required to tell patients that a drug is off-label.

    "Off-label prescribing isn't necessary bad." "It can be beneficial,
    when patients have exhausted other approved options, as with cancer."

    "A 2008 study found that 8 of 10 cancer doctors surveyed had prescribed drugs off-label." Recent studies quote certain cancer therapies, treatments and drugs as same.

  • snowflakeformationxy snowflakeformationxy May 1, 2015 1:57 PM Flag

    This CEO is easy to read and always has been. Most drug CEOs know the score going into the ninth ending if not long before. This reading is approval. Read the books and writings of Dr. Angell who was a former editor in chief of the prestigious New England Journal of Medicine. She is currently a senior lecturer in social medicine at Harvard Medical School. She will tell you how to read the scoring.

  • snowflakeformationxy snowflakeformationxy Apr 30, 2015 10:17 PM Flag

    Good points, but company may not need to do another offering if Meteor results are positive.
    I posted this reference in Feb.

    David Miller @AlpineBV_Miller ---- a partner of Alpine Bioventures
    Tweet: Question now is when does $RHHBY take out $EXEL ? Just a question of timing at this point.
    Subject that Roche will buy up to half of company. This would give them first pick on anything within pipeline, on the lab tables or in the mice cages.
    Second - Roche would have advantage tax status. Full deductions for research costs. More of importance: Company and Roche would share administration costs including payroll.
    This is very probable now per Saltydog posting on employee share plan.

  • snowflakeformationxy snowflakeformationxy Apr 30, 2015 7:13 PM Flag

    Wilder, that's the true. Investors and medical types follow Ohad Hammer. One article of continued reference on social media and with other contact research is - Open Reading Frame - Analyzing Biotech Stocks - March 30, 2014. Upon any approvals in the coming years, revenue is key from medical prescription.

  • Reply to

    Looks like to me

    by itssofine2 Apr 29, 2015 1:19 PM
    snowflakeformationxy snowflakeformationxy Apr 29, 2015 6:46 PM Flag

    If we put every person in jail for manipulation, there would be no one in government and on Wall Street: half the population would be in jail. LOL. Hug your dog, a true honest being.

  • Reply to

    ipilimumab Plus nivolumab "dissolves tumor"

    by socialidiocies Apr 28, 2015 4:42 PM
    snowflakeformationxy snowflakeformationxy Apr 29, 2015 1:21 AM Flag

    The research isn't surprising as new. NEJM has dated articles going back to 2011. I don't see much variance in results from ASCO 2014.

  • Reply to

    CKIN 2015

    by wilderguide Apr 18, 2015 6:55 AM
    snowflakeformationxy snowflakeformationxy Apr 18, 2015 3:43 PM Flag

    Off topic, but I found this today while researching the politics of drug acceptance use between Ireland, Scotland, England and Central/Northern Europe.

    ScienceDirect - Critical Reviews in Oncology/Hematology - Volume 93. Issue 1, Pages 60-73.

    "Despite being considered to be well tolerated, both sorafenib and lenvatinib have shown a remarkable toxicity, which has led to dose reductions in the majority of patients and to treatment discontinuation in a significant proportion of cases. The role of KIs in differentiated TC may be revolutionised by the finding that selumetinib may restore a clinical response to radioactive iodine (RAI). Vandetanib and cabozantinib have been approved for the treatment of advanced, progressive medullary TC (MTC). Nevertheless, the toxicity of both compounds suggests their selective use in those patients with strong disease progression."

  • Reply to

    Meteor Test Result bar to hurdle

    by ulingt Apr 17, 2015 8:36 AM
    snowflakeformationxy snowflakeformationxy Apr 17, 2015 1:01 PM Flag

    MGH - Harvard Medical has a lot of reference to dosing - and prior studies.
    Abstract 90 - Cancer Center - prior Cabo review.- based on Sargent one-stage design. Studies definitions are as good as any in noting gastro hemorrhage.

  • snowflakeformationxy snowflakeformationxy Apr 17, 2015 12:11 AM Flag

    Go to 'Short Squeeze' and place EXEL into symbol box.

  • Reply to

    a question about "crossover"

    by stocklooking Apr 16, 2015 4:13 AM
    snowflakeformationxy snowflakeformationxy Apr 16, 2015 8:47 AM Flag

    Go to 'crossover study' Wikipedia. It's a quick straight-forward read.

  • Reply to

    METEOR Sighting?

    by rad.onco Apr 15, 2015 2:58 PM
    snowflakeformationxy snowflakeformationxy Apr 15, 2015 9:48 PM Flag

    There is one common major concern throughout an ongoing biotech trial and that is hospitalization due to fever. Of course a class course of fever therapy can be given if there is a need. We were told to expect top-line results and I expect that the company this time around has pertinent communication with the FDA. This time, before decision, I will hold my shares. I don't believe that there's a lot of professional outright shorts without participation with option designs. Calls were cheap, as call investors tripled their money from earlier this year. Calls are still inexpensive and that is reverse insurance for professional shorts.

  • snowflakeformationxy snowflakeformationxy Apr 13, 2015 1:02 AM Flag

    Thanks. It's good luck to use the words VooDoo and concoction in the same sentence.
    semanresu - Feb 25 2015
    emanresu_retne_esaelp - Apr 29 2014

  • Reply to


    by saltydog711 Apr 11, 2015 11:51 AM
    snowflakeformationxy snowflakeformationxy Apr 12, 2015 12:59 PM Flag

    Saltydog, I wish you good luck as well. I had taken a couple of law courses in college. . I'd had various research based positions in a few different areas throughout life. I'm been retired for a few years due to health. I have always had a concern for homeless animals. Either I adopt them, or I find homes for them. I live in a putdown County.

  • Reply to

    Update: Cabo in CRC

    by wilderguide Apr 11, 2015 11:51 AM
    snowflakeformationxy snowflakeformationxy Apr 12, 2015 3:58 AM Flag

    That Cancer Discovery study has reference to:
    Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal cancer survival. N Engl J Med 2012;367:1596–606.

    Over the last couple of years, I'd came across several different cancer type studies with aspirin in relation to P1K3CA - mutant tumors. The ASCO POST, November 1, 2013 Volume 4 Issue 2. Cancernetwork and Medscape.

    I just up late and I'm presently examining the P1K3CA patents held by Exelixis. It somewhat appears that they saying - guess what, we already have some of this on file. So I thought that I just throw that post up.

  • Reply to

    Update: Cabo in CRC

    by wilderguide Apr 11, 2015 11:51 AM
    snowflakeformationxy snowflakeformationxy Apr 12, 2015 2:20 AM Flag

    Regular use of aspirin following diagnosis has been associated with significantly longer cancer-specific and overall survival only among patients with PIK3CA-mutant tumors. Patients with PIK3CA-mutant tumors, 26% of those who did not use aspirin died within 5 years of diagnosis, compared with only 3% of patients who took aspirin.

  • Reply to


    by saltydog711 Apr 11, 2015 11:51 AM
    snowflakeformationxy snowflakeformationxy Apr 11, 2015 9:56 PM Flag

    Salty - A well worded charting post. Value score, fundamental score and valuation is looking good. Barchart technical is at 88% - a strong buy.

    During the month of March and early April, I spent about 20 hours trying to flowchart the patents that I found and posted to possible locks on procedural use by other researchers. Wilder posted some thoughts and comparisons. I'm using a large poster board with a dry erase marker. I'm probably only one-third there. It has been difficult, but I think so-far somewhat accurate. At least I know that the legal values are strong per medical intend law. In just, as stated by the Roche's CEO, visions of a Roche partnership will remain in place. If Exelixis needs support, Roche could become a principal partner. I think that Roche realizes the values of the patents held by Exelixis.

  • snowflakeformationxy snowflakeformationxy Apr 11, 2015 8:13 PM Flag

    Instead of posting this as thread post #13, I will post here where it can't be hidden.
    Place in your browser
    Place in your browser - total number of fast tracks that get approved
    It's the second one down on Bing and has a {PDF} format
    There is also data and a chart on NMEs for the last decade. A ten year historic comparison is given.
    It often takes the FDA (time) before subject matter is web published. I don't believe that subject matter in (whole) is yet available for 2014.

  • snowflakeformationxy snowflakeformationxy Apr 10, 2015 11:53 PM Flag

    I would focus fast tracking/status/approvals on the area of medicine that applies - cancer and type. There are sites that discuss trials and approvals on cancer. That's been a popular subject here as in study/treatment comparisons. I would just go back and read some of the posts by the regulars here.

15.82-0.01(-0.06%)May 1 4:00 PMEDT